- Home
- SPAI vs PYXS Comparison
SPAI vs PYXS Comparison
Compare SPAI & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SPAI | PYXS |
|---|---|---|
| Founded | 2021 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 127.2M | 141.3M |
| IPO Year | 2024 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SPAI | PYXS |
|---|---|---|
| Price | $4.70 | $3.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $10.00 | $7.00 |
| AVG Volume (30 Days) | 250.3K | ★ 1.4M |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.03 |
| EPS | ★ N/A | N/A |
| Revenue | $606,681.00 | ★ $13,858,000.00 |
| Revenue This Year | $1,060.58 | N/A |
| Revenue Next Year | $162.46 | $7,043.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.23 | $1.03 |
| 52 Week High | $9.16 | $5.55 |
Technical Indicators
Market Signals| Indicator | SPAI | PYXS |
|---|---|---|
| Relative Strength Index (RSI) | 53.80 | 55.72 |
| Support Level | $3.65 | $1.37 |
| Resistance Level | $5.61 | $3.45 |
| Average True Range (ATR) | 0.50 | 0.41 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 38.34 | 66.19 |
Price Performance
Historical ComparisonAbout SPAI Safe Pro Group Inc.
Safe Pro Group Inc operates to acquire security and protection products. The company operated in three reportable business segments, which consisted of the business of Safe-Pro USA, the business of Airborne Response, and the business of Safe Pro AI. The majority of revenue is from Safe-Pro USA.
About PYXS Pyxis Oncology Inc.
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.